Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, has been awarded a $659,538 Lisa Dean Moseley Foundation grant to further her team’s triple-negative breast cancer research.
Dr. Sims-Mourtada and her team investigate the role of cells immediately around a tumor and their impact on triple-negative breast cancer, which is resistant to current therapies and disproportionately affects premenopausal women and African American women.
“The Moseley Foundation’s grant will help our breast cancer research team address a pressing concern for Delaware, which has the highest rate of triple-negative breast cancer in the nation,” said Nicholas J. Petrelli, M.D., medical director of the cancer center, in a press statement.
Before receiving the grant, Dr. Sims-Mourtada’s team found that an anti-inflammatory drug that is used to treat rheumatoid arthritis may have the potential slow the growth of cancer stem cells and triple-negative breast cancer tumors. They will now further research the relationship between cancer stem cells and inflammation by comparing pre- and post-chemotherapy breast tissue.
How $365K in financial literacy funding will be distributed in Delaware
Free tech training program ITWorks gets a $10K boost from M&T Bank
How virtual reality can be used to prevent opioid deaths
Packed with growth opportunities, WSFS Bank moves into Philly
The SBA is helping Delaware companies defray the costs of doing business internationally
Talos Tech scores $100K in SBIR funding
Wilmington smart fashion startup edging toward $50K grant
These hiring companies want to meet you at NET/WORK Suburbs
Sign-up for daily news updates from Technical.ly Delaware